Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer

Fifteen patients with treatment-refractory colorectal cancer were enrolled on a phase 1b study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia designed to selectively replicate in cancer cells. Pexa-Vec was administered intravenously every 14 days, at do...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Ther
Main Authors: Park, Se Hoon, Breitbach, Caroline J, Lee, Jeeyun, Park, Joon Oh, Lim, Ho Yeong, Kang, Won Ki, Moon, Anne, Mun, Jae-Hee, Sommermann, Erica M, Maruri Avidal, Liliana, Patt, Rick, Pelusio, Adina, Burke, James, Hwang, Tae-Ho, Kirn, David, Park, Young Suk
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2015
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4817877/
https://ncbi.nlm.nih.gov/pubmed/26073886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2015.109
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados